Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Syndax Pharmaceuticals SNDX announced positive top-line results for revumenib, an oral small-molecule menin inhibitor, from the AUGMENT-101 study. The results were announced from the relapsed or ...
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Syndax price target lowered to $18 from $23 at Scotiabank
Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...
Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market Undervaluation
Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...
The New York Times23h
New York Times - Top Stories
Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...
NDTV5h
World News
More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.